Or if you're already a Pharma IQ member, sign in below to download. Sign In Join
The epidemiology of increasing resistance problem continues to garner much attention. A bacteria capable of opposing the inhibitory (bacteriostatic) or killing (bacteriocidal) effects of antibiotics has unfortunately become an increasingly common occurrence and presents a serious threat to successful treatment of bacterial infections.
In this interview Dr. Mark Brian Anderson, Chief Scientific Officer at NovaBay Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about the growing market demand for novel anti-infective drugs and the key scientific challenges to antibiotic drug discovery and development. Anderson also shares his insights on what the industry is doing to combat resistance, which presents a huge market inhibitor.